BT and Schrödinger team up on drug discovery
6 June 2013Tweet
BT and Schrödinger are working together to accelerate the process of drug discovery and development using the BT for Life Sciences cloud platform and Schrödinger’s scientific software applications.
As part of the initiative, Schrödinger becomes a strategic member of the BT for Life Sciences partner ecosystem, helping provide research solutions to scientists on a global basis. Schrödinger’s software tools will be integrated into BT for Life Sciences as part of BT’s R&D Workbench environment.
Built on the BT Cloud Compute platform and unveiled at the 10th Annual BioIT World meeting last year, BT for Life Sciences is the first cloud service designed to enable collaboration within the life sciences industry for increased productivity in discovery, research and development.
One of Schrödinger’s key applications, hosted Seurat, will soon be available on the BT Cloud Compute Platform. This application contains tools that help researchers in the discovery and optimisation of drug research and provides a means for sharing real-time analysis across the organisation. Using the BT platform, Schrödinger can easily integrate data and scientific business processes, enhancing the early discovery process so that ultimately better compounds can be brought to the clinic faster.